Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN114277023B details a biocatalytic route for nicotinamide using recombinant enzymes and ion exchange resin for superior purity and cost efficiency.
Patent CN109957585B reveals a high-efficiency ketoreductase process for chiral alcohol intermediates, offering significant cost reduction and scalable supply chain solutions.
Patent CN114032258B reveals enzymatic route for L-butylphthalide intermediate. Offers high purity and cost efficiency for pharmaceutical supply chains.
Patent CN110452920A reveals high-efficiency enzymatic route for L-phenylglycine, offering supply chain stability and cost reduction for pharmaceutical intermediates manufacturing.
Analysis of patent CN1282746C reveals a microbial route for high-purity beta-amino alcohols, offering significant cost reduction in API manufacturing and reliable supply chain solutions.
Patent CN104560905B reveals green enzymatic route for chiral sulfoxides. Enables cost reduction and sustainable supply chain for pharmaceutical intermediates manufacturing globally.
Patent CN107384885B reveals enzymatic synthesis of chiral amines. Achieve cost reduction in API manufacturing with high conversion and optical purity.
Patent CN101974604A reveals a green enzymatic route for paroxetine intermediates using ionic liquids, offering high purity and reduced environmental impact for API manufacturing.
Patent CN110835639A reveals a dual-enzyme DKR process for high-purity (S)-tetrahydroisoquinoline derivatives, offering superior ee values and scalable manufacturing for pharmaceutical intermediates.
Patent CN109182410B details a high-yield biocatalytic route for chiral piperidine intermediates, offering significant cost reduction in API manufacturing and superior supply chain reliability.
Patent CN109852593B details a high-activity CmCR mutant for R-3HB production, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN113174377A reveals stable carbonyl reductase mutants for high-yield diltiazem intermediate synthesis, offering cost-effective biocatalysis solutions.
Patent CN114736882A discloses high-performance monoamine oxidase mutants for asymmetric oxidation, enabling cost reduction in API manufacturing and reliable supply.
Patent CN110835639B reveals a high-efficiency enzymatic route for producing chiral tetrahydroisoquinoline intermediates with superior stereoselectivity and scalable manufacturing potential.
Novel dehalogenase method for pitavastatin intermediates offers high purity and yield. Reduces environmental impact and enhances supply chain reliability for pharmaceutical manufacturers globally.
Patent CN111411095B discloses a novel recombinant (R)-ω-transaminase mutant with high activity and stereoselectivity for efficient sitagliptin intermediate production, ensuring supply chain stability.
Patent CN112094856B discloses high-efficiency transaminase mutants for sitagliptin synthesis, achieving >99.95% e.e. and enabling significant cost reduction in API manufacturing.
Patent CN105492606A enables efficient (-)-vibo-quercitol production via novel reductase, offering high purity and cost reduction for pharma intermediates.
Novel hydroxylase method reduces cis-3-hydroxy impurity for pharmaceutical intermediates. Scalable biocatalysis ensures cost efficiency and supply reliability.
Patent CN108893455A details a transaminase mutant for L-glufosinate-ammonium production. Achieves 98% yield and 99% ee. Ideal for agrochemical intermediate supply chains seeking cost reduction.